The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 16, 2018
Filed:
Aug. 29, 2016
Applicant:
Florida A&m University, Tallahassee, FL (US);
Inventors:
Mandip Sachdeva, Tallahassee, FL (US);
Ketankumar Patel, Tallahassee, FL (US);
Assignee:
Florida A&M University, Tallahassee, FL (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); A61K 31/7088 (2006.01); C12N 15/113 (2010.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/48 (2006.01);
U.S. Cl.
CPC ...
A61K 31/519 (2013.01); A61K 9/0014 (2013.01); A61K 31/7088 (2013.01); A61K 47/18 (2013.01); A61K 47/22 (2013.01); A61K 47/48046 (2013.01); C12N 15/1136 (2013.01); C12N 2310/14 (2013.01); C12N 2310/3515 (2013.01); C12N 2320/31 (2013.01); C12N 2320/32 (2013.01);
Abstract
A pharmaceutical formulation and topical administration thereof for the treatment of psoriasis or any one or more symptoms associated therewith. The formulation contains a therapeutically effective amount pemetrexed alone as the active agent or can contain therapeutically effective amounts of pemetrexed in combination with siRNA-inhibiting TNFα. The formulation may further include a cationic surfactant, such as cetylpyridinum chloride, and urea for enhanced permeation through the stratum corneum of the patient or subject.